Aurobindo Pharma Limited

NSE: AUROPHARMA

Healthcare Healthcare

₹1,624.5

-1.25%EOD · 19 Aug

Aurobindo Pharma Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap

₹93,470 Cr

52W Range

₹1682 / ₹1016

Volume

752K

58.4% delivery

1Y Return

+54.7%

P/E Ratio

25.3

P/B Ratio

2.5

ROE

9.9%

Debt / Equity

21.31

Peers in Healthcare

Top 8 by market cap

Company	LTP	Market Cap	P/E	P/B	ROE %	Div Yld %
Aurobindo Pharma Limited(this stock)	₹1,624.5	₹93,470 Cr	25.3	2.5	9.9%	0.24%
Divi's Laboratories LimitedDIVISLAB	₹8,560	₹2.27 L Cr	87.5	13.4	16.2%	0.35%
Torrent Pharmaceuticals LimitedTORNTPHARM	₹5,013	₹1.91 L Cr	76.9	19.5	17.0%	0.79%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP	₹8,750	₹1.26 L Cr	61.4	13.5	21.5%	0.23%
Zydus Lifesciences LimitedZYDUSLIFE	₹1,104.5	₹1.10 L Cr	25.3	4.2	18.3%	0.09%
Mankind Pharma LimitedMANKIND	₹2,394	₹98,871 Cr	49.0	6.1	12.4%	0.08%
Laurus Labs LimitedLAURUSLABS	₹1,801.8	₹97,353 Cr	88.6	18.2	17.7%	0.13%
Max Healthcare Institute LimitedMAXHEALTH	₹997	₹97,036 Cr	67.7	9.1	14.3%	0.20%
Aster DM Healthcare LimitedASTERDM	₹800.2	₹69,751 Cr	133.1	9.3	10.1%	0.48%

Technical Indicators

Full analysis · objective math, not advice

Returns

-1.2%

-2.3%

+6.0%

+11.1%

+32.6%

+54.7%

Weinstein Stage

Stage 2 — Advancing (uptrend)

RSI (14)

63 Neutral

Trend Template

7/7strong

RS vs Nifty (3M)

+9.8pp

Moving Averages (price vs MA)

20-DMA

₹1616

above

50-DMA

₹1581

above

150-DMA

₹1426

above

200-DMA

₹1367

above

From 52W High

-3.4%

From 52W Low

+53.1%

Support (20D)

₹1537

Resistance (20D)

₹1682

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Quality Signals

Multi-year consistency · Source: Screener annual data

ROE Consistency

0/0 years ≥15%

Revenue Growth

+3.0% CAGR

Up 9 of last 11 years

Earnings Quality

Fully cash-backed

OCF / Net Profit = 1.21x · 12/12 yrs +ve cash flow

Quality signals derived from multi-year annual financials. ROE consistency = years with ≥15% return on equity. Cash-backed = operating cash flow vs reported net profit (≥1x means earnings are converted to real cash, not just accruals). Educational reference only — not investment advice.

News & FilingsGoogle News + BSE

News via Google News · Not verified by IPOpulse · Not investment advice

Community discussion(0)

No comments yet — be the first to share your view.